These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 32487192

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
    Liu AM, Xu Z, Shek FH, Wong KF, Lee NP, Poon RT, Chen J, Luk JM.
    PLoS One; 2014; 9(1):e86872. PubMed ID: 24466275
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
    Hu W, Lu SX, Li M, Zhang C, Liu LL, Fu J, Jin JT, Luo RZ, Zhang CZ, Yun JP.
    Oncotarget; 2015 Mar 30; 6(9):6570-83. PubMed ID: 25788265
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
    Chen Z, Lu X, Wang Z, Jin G, Wang Q, Chen D, Chen T, Li J, Fan J, Cong W, Gao Q, He X.
    Oncotarget; 2015 Feb 10; 6(4):2538-48. PubMed ID: 25576919
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
    Xu Q, Tu J, Dou C, Zhang J, Yang L, Liu X, Lei K, Liu Z, Wang Y, Li L, Bao H, Wang J, Tu K.
    Mol Cancer; 2017 Dec 20; 16(1):178. PubMed ID: 29262861
    [Abstract] [Full Text] [Related]

  • 9. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
    Feng J, Dai W, Mao Y, Wu L, Li J, Chen K, Yu Q, Kong R, Li S, Zhang J, Ji J, Wu J, Mo W, Xu X, Guo C.
    J Exp Clin Cancer Res; 2020 Jan 30; 39(1):24. PubMed ID: 32000827
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma.
    Ng KT, Yeung OW, Liu J, Li CX, Liu H, Liu XB, Qi X, Ma YY, Lam YF, Lau MY, Qiu WQ, Shiu HC, Lai MK, Lo CM, Man K.
    Int J Oncol; 2020 Oct 30; 57(4):956-966. PubMed ID: 32945373
    [Abstract] [Full Text] [Related]

  • 11. Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma.
    Roth GS, Teyssier Y, Abousalihac M, Seigneurin A, Ghelfi J, Sengel C, Decaens T.
    World J Gastroenterol; 2020 Jan 21; 26(3):324-334. PubMed ID: 31988592
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
    Wong CC, Au SL, Tse AP, Xu IM, Lai RK, Chiu DK, Wei LL, Fan DN, Tsang FH, Lo RC, Wong CM, Ng IO.
    PLoS One; 2014 Jan 21; 9(12):e115036. PubMed ID: 25541689
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
    Yoo SH, Kwon JH, Nam SW, Lee JY, Kim YW, Shim DJ, Lee SW, Jang JW.
    Cancer Control; 2020 Jan 21; 27(2):1073274820935843. PubMed ID: 32583687
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
    Feng J, Wu L, Ji J, Chen K, Yu Q, Zhang J, Chen J, Mao Y, Wang F, Dai W, Xu L, Wu J, Guo C.
    J Exp Clin Cancer Res; 2019 May 17; 38(1):204. PubMed ID: 31101057
    [Abstract] [Full Text] [Related]

  • 18. MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma.
    Soliman MH, Ragheb MA, Elzayat EM, Mohamed MS, El-Ekiaby N, Abdelaziz AI, Abdel-Wahab AA.
    Anticancer Agents Med Chem; 2021 May 17; 21(2):246-253. PubMed ID: 32416702
    [Abstract] [Full Text] [Related]

  • 19. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M, Webber G, Prajapati HJ, Chen Z, El-Rayes B, Spivey JR, Pillai AA, Kim HS.
    J Gastroenterol Hepatol; 2015 Jul 17; 30(7):1167-74. PubMed ID: 25675849
    [Abstract] [Full Text] [Related]

  • 20. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma.
    Sciarra A, Ronot M, Di Tommaso L, Raschioni C, Castera L, Belghiti J, Bedossa P, Vilgrain V, Roncalli M, Paradis V.
    Liver Int; 2015 Nov 17; 35(11):2466-73. PubMed ID: 25865109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.